X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

OncoTargets and Therapy

期刊標題檢索 ONCOTARGETS THE 最新評論: Seriously, the review fee or page fee is $3000, which instantly disco... (2024-07-17)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[OncoTargets and Therapy]您好,您是該頁面的第 183285 位訪客。

期刊簡介
期刊名稱OncoTargets and Therapy OncoTargets and Therapy
LetPub Score
4.9
51 ratings
Rate

Reputation
3.5

Influence
5.2

Speed
9.2

期刊簡稱ONCOTARGETS THER
ISSN1178-6930
h-index44
CiteScore
CiteScoreSJRSNIPCiteScore Rank
9.700.8100.648
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q123 / 272
Category: Medicine
Subcategory: Oncology
Q165 / 404

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
官方網站https://www.dovepress.com/oncotargets-and-therapy-journal
在線稿件提交https://www.dovepress.com/submit_step_1.php
開放訪問Yes
出版商Dove Medical Press Ltd.
主題領域BIOTECHNOLOGY & APPLIED MICROBIOLOGY
出版國/地區ENGLAND
發行頻率
創刊年2008
每年文章數75每年文章數趨勢
黃金OA百分比96.46%
OA Related Info
APC: Yes( USD2990; )
APC waiver:Check Notes
Other charges: No
Keywords: oncology、cancer、therapeutic agents
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOTECHNOLOGY & APPLIED MICROBIOLOGYSCIEQ390/174
ONCOLOGYSCIEQ3163/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-6930%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【OncoTargets and Therapy】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature CancerH-index: 0

    CiteScore: 31.10
    JAMA OncologyH-index: 41

    CiteScore: 37.50
    JAMA OncologyH-index: 61

    CiteScore: 37.50
    Trends in CancerH-index: 0

    CiteScore: 28.50
    Liver CancerH-index: 25

    CiteScore: 20.80
    Experimental Hematology & OncologyH-index: 0

    CiteScore: 12.60
    ESMO OpenH-index: 0

    CiteScore: 11.70
    Cancer Biology & MedicineH-index: 29

    CiteScore: 9.80
    Annual Review of Cancer BiologyH-index: 0

    CiteScore: 14.50
    CancersH-index: 53

    CiteScore: 8.00
    學科內最受檢索的期刊 頁面查看次數
    Cancers209506
    Cancer Management and Research149109
    Journal of Oncology88245
    Cancer Biology & Medicine58478
    Molecular Therapy-Oncolytics43576
    JAMA Oncology36961
    Liver Cancer34135
    Nature Cancer33325
    Translational Lung Cancer Research29416
    JAMA Oncology28793
  •  

    OncoTargets and Therapy OncoTargets and Therapy
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/50)
  [OncoTargets and Therapy] 的評論撰寫評論
作者: 可歆三岁啦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-17 09:45:35 評論於
Seriously, the review fee or page fee is $3000, which instantly discourages me.
(0) 讚! | 可歆三岁啦

作者: 法慧世暄


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-12 17:57:33 評論於
Excuse me, how long has it been since 2a?
(0) 讚! | 法慧世暄

作者: 一只素芬呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-28 10:48:19 評論於
Regrettably~~~~~~Our出版政策规定,每篇手稿必须至少有两组同行审稿意见,以便编辑决策者能够对手稿做出结论。不幸的是,尽管我们经过多周的努力,仍未能获得您手稿所需的审稿人数。为了不进一步延迟您的手稿,主编决定拒绝您的手稿,以便您可以与其他出版商联系,他们可能更能找到合适的审稿人
(0) 讚! | 一只素芬呀

作者: 一只素芬呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-22 10:22:49 評論於
1. We started inviting reviewers on the 7th. 2. We only invited one on the 4th, and as of the 23rd, we have not yet invited a second. The journal requires at least two reviewers, and we are unsure how long it will take
(0) 讚! | 一只素芬呀

作者: 一只素芬呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-22 10:13:36 評論於
You can remind them, I have reminded them before and they responded quite promptly, but the progress did not speed up
(0) 讚! | 一只素芬呀

作者: 明冠文柏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-01 13:23:48 評論於
It's been a month already, and I'm still in 1A. Does this mean I have no chance? Should I send a reminder?
(0) 讚! | 明冠文柏

作者: 明冠文柏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-31 10:43:19 評論於
Review speed: 2.0 Experience sharing: 1A It has been a month, is there still hope, do I need to urge for review?
(0) 讚! | 明冠文柏

作者: 一只素芬呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-23 21:26:27 評論於
It has been two weeks, can't find reviewers? Should we remind the editor?
(0) 讚! | 一只素芬呀

作者: 天罡和通


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-21 17:01:26 評論於
I want to ask what does 7f mean in this magazine?
(0) 讚! | 天罡和通

作者: 回风嘉蕊


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-08 20:12:06 評論於
It's been almost two weeks for me
(0) 讚! | 回风嘉蕊

作者: 龙象诗晗


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-17 18:18:03 評論於
What does 5A mean in terms of scientific research?
(0) 讚! | 龙象诗晗

作者: Isaac Jenkins


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-13 17:29:18 評論於
It's been 4 days since the interview. Xiao Xiu, do you think the chances of being hired are high?
(0) 讚! | Isaac Jenkins

作者: 一只诗蕾呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-29 23:40:43 評論於
Could I ask you a question? I received this revision, "As part of our compliance checks we have noted the following outstanding requirements:- provide Figure 1-6 as a 'one combined' PDF file only". Does this mean I need to upload all the images in one PDF file? But I thought the submission guidelines required one image per file? Hope you can reply to me. Urgent!
(0) 讚! | 一只诗蕾呀

作者: 上清雨真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-29 23:19:59 評論於
Please combine the figures 1-** into one PDF file
(0) 讚! | 上清雨真

作者: 混元新曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-20 14:13:36 評論於
It definitely is necessary
(0) 讚! | 混元新曦

作者: 控鹤馨月


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-04 21:14:51 評論於
Focus of research: Tumors; Basic experiments; Experience sharing on small RNA: Original uncropped WB gel images with ladder data are needed
(0) 讚! | 控鹤馨月

作者: 八荒涵容


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-24 22:35:10 評論於
The review before submission is very strict, and I have already made several revisions. Yesterday, I was informed that the reviewers have been invited, and today I was asked to resubmit a single original image as 1E. The combined original images I submitted before are not accepted. I hope for a positive outcome
(0) 讚! | 八荒涵容

作者: 法慧若曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-15 15:34:16 評論於
After 14 days, there has been no progress from 1a to 1AB. It is suggested that students in a hurry take a detour, as progress has been slow recently
(0) 讚! | 法慧若曦

作者: 法慧若曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-06 23:09:30 評論於
What's going on, 1a is still 1a after a week, can we push for the manuscript?
(0) 讚! | 法慧若曦

作者: 是书蝶吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-21 13:35:29 評論於
Hello, do we need to stitch the raw data's white balance?
(0) 讚! | 是书蝶吖

作者: 是书蝶吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-21 09:16:49 評論於
Hello, can original strips be trimmed?
(0) 讚! | 是书蝶吖

作者: 北斗冰双


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-18 18:41:37 評論於
Do you need all the original data and raw footage for the magazine?
(0) 讚! | 北斗冰双

作者: 是书蝶吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-14 16:02:12 評論於
Hello, may I ask how long you have been waiting for your 1a? It's been 8 days for me
(0) 讚! | 是书蝶吖

作者: 是书蝶吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-13 14:53:38 評論於
Hello, may I ask how long have you been using 1A? Mine has been stuck for a week too
(0) 讚! | 是书蝶吖

作者: 是书蝶吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-13 14:44:20 評論於
Hi, may I ask how long you have been using your 1A? It's been a week since I got my card
(0) 讚! | 是书蝶吖

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/50)

開始撰寫 [OncoTargets and Therapy] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*